Initiate

We're excited to announce the launch of our brand new website! We've implemented a modern, user-friendly design; uploaded a bank of examples of previous success stories; and added an easy way to see our publications, podcasts, and upcoming conferences and webinars. A big thank you to Geek Designs for helping us to realise our vision! To check it out, visit https://lnkd.in/dqe428Cx. #Marketaccess #HEOR #Newwebsite #Webdesign

Reach out to our talented Senior Consultant Adelaide Shaw-Maguire whilst at #ESMO2024 to see how we can help you achieve your oncology reimbursement goals! #Marketaccess #HTA #HEOR #Oncology

At Initiate, we believe that the key to successful health technology submissions lies in combining strategic foresight with experienced leadership. Our process reduces client effort, maximizes learning retention, and guarantees a consistent high-quality process. This approach was critical in managing complex HTAs across multiple indications, see case study below! Ready to discuss how our tailored solutions can help your submission process? Reach out to hello@initiateconsultancy.com #hta #strategy #oncology

Are you attending the ESMO congress? Connect with Adelaide Shaw-Maguire to discuss your oncology project requirements.

The JCA timeline challenge Companies will need to act decisively and early to fully map and understand market dynamics in the relevant European member states under the new JCA process. With just 90 days to write the submission following receipt of finalised PICOs, poor preparation, and understanding will inevitably hamper the chances of delivering access and increase pressure on those developing the JCA submission. Initiate have developed a methodology that allows us to support our clients ahead of scoping, anticipating possible challenges, reducing the risk of poor preparation, and ensuring submissions have the highest chance of success. The PICO issue For the JCA report to fulfil its objective of accelerating patient access to new treatments across Europe by increasing transparency and reducing duplication of country level HTA, the scoping process will be critical. The starting point for any HTA is defining the PICO: population, intervention, comparators and outcomes. Manufacturers in this process may face several challenges: PICOs may diverge between countries; PICOs requested by member states may not align with available clinical studies; Perceptions of validity of endpoints may differ between member states; Member states may differ in their acceptance of methods of analysing clinical trial data. PICORadar At Initiate we have developed our solution-focused process to support clients initiating their preparations for JCA. The PICORadar builds upon our Reimbursement Radar insight work which tracks HTA outcomes in key markets. Our process builds insight across all member states, developing deep understanding of current modalities and methods of care, validating focus with Payers, and leads our expert team to the development of the minimum number of PICOs, enabling clients to focus on early development of JCA submissions. The PICORadar is a perfect blend of artificial intelligence (AI) for efficient identification of PICO criteria and essential human intelligence (HI) to validate and quality check output. The PICORadar process is designed to support the writing and development of the JCA submission ahead of the scoping to reduce pressure and allow strategic decision making based upon predicting likely PICOs. If you would like to discuss any of the developments outlined above, discover more about PICORadar, or discuss your market access and HEOR needs, please get in touch at hello@initiateconsultancy.com.

Join Initiate's Andrew Mumford in this Life Science Access Academy masterclass discussing how the Celtic Nations are progressing in the current environment and the prospect of yet more change as fiscal pressures bite. #masterclass #nhsupdate #celticnations

Did you know Initiate has a Spotify podcast channel? Take a listen to deep dive into the realm of health economics and market access. To follow the Initiation podcast on Spotify simply click the link below to make sure you don't miss any episodes, insightful discussions and updates. Keep an eye out for new episodes coming soon! Previous episodes include: ·      A conversation with Stuart Hann, The Blind Chocolatier about his route diagnosis with LHON and his incredible journey to opening and running a successful chocolate business. ·      A conversation with Andi Orlowski and David Sgorbati at the Health Economics Unit on sourcing and using high-quality data for reimbursement purposes. ·      Living with LHON. A conversation with Lily Mumford about her inspiring story of adjusting to living with LHON. ·      Insight from the “023 Reimbursement Radar wrap-up we present a summary of our findings in this episode. From market-level differences to leading disease areas, find out about drug reimbursement trends for 2023 in 13 key HTA markets. ·      Developing PROMS in rare diseases. A conversation on patient-reported outcome measures (PROMs) in rare diseases. ·      Working with Initiate. What can you expect working with our market access and health economics consultancy? https://lnkd.in/ePrHyXy6 #marketaccess #healtheconomics #podcast #insights

Don't miss our value and access experts discussing "Valuing Value: Defining Pharmaceutical Value in 2024" at this Life Science Access Academy live-streamed masterclass on 10th September 2024. Jonathan Gibson Jane Moorhouse Adelaide Shaw-Maguire #masterclass #marketaccess #HTA #value

The Initiate team are excited to announce that eight of our research poster abstracts have been accepted for presentation at ISPOR EU 2024! These posters cover a diverse range of topics, from analysis of reimbursement outcomes in the Orphan drug space (across Europe and a focus on Ireland and Germany) to discussions around the Joint HTA process and traditional launch sequencing. Some disease-specific research includes carer burden modelling in Spinal Muscular Atrophy, and the cost-effectiveness of immunotherapies for advanced or recurrent endometrial cancer. A big thank you to our incredible team for their hard work and commitment to demonstrating their knowledge and expertise in reimbursement, market access and health economics. We look forward to discussing our research with you in Barcelona! #ISPOREU2024 #HealthEconomics #OutcomesResearch #Teamwork #Research #Posters

Rounding up Initiate's Reimbursement Radar series for Q1 & Q2 2024, @Georgia Roberts reports on the reimbursement decisions made in obstetrics and gynaecology. Keep an eye out for our Q3 Reimbursement Radar posts in October! If you would like to know more do get in touch and follow Initiate for more insights on reimbursement decisions across different disease areas. #ReimbursementRadar #HTA #HEOR #MarketAccess #Obstetrics #Gynaecology